CytomX Therapeutics, Inc. (CTMX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
CTMX Revenue Growth
CTMX Revenue Analysis (2014–2025)
As of May 8, 2026, CytomX Therapeutics, Inc. (CTMX) generated trailing twelve-month (TTM) revenue of $35.5 million, reflecting significant decline in growth of -79.9% year-over-year. The most recent quarter (Q1 2026) recorded $10.3 million in revenue, up 1447.2% sequentially.
Looking at the longer-term picture, CTMX's 5-year compound annual growth rate (CAGR) stands at +2.2%, indicating moderate growth over time. The company achieved its highest annual revenue of $138.1 million in 2024.
When compared to Healthcare sector peers including RCUS (+67.4% YoY), PBYI (-2.4% YoY), and AGEN (+10.4% YoY), CTMX has underperformed the peer group in terms of revenue growth. Compare CTMX vs RCUS →
CTMX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| CTMXCurrent | $36M | -79.9% | +2.2% | -25.7% | |
 RCUS | $247M | +67.4% | +25.9% | -156.3% | |
 PBYI | $228M | -2.4% | +0.3% | 16.3% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
CTMX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $76.2M | -44.8% | $76.2M | 100.0% | $-19,564,000 | -25.7% |
| 2024 | $138.1M | +36.4% | $138.1M | 100.0% | $25.0M | 18.1% |
| 2023 | $101.2M | +90.4% | $101.2M | 100.0% | $-6,484,000 | -6.4% |
| 2022 | $53.2M | +42.5% | $53.2M | 100.0% | $-101,335,000 | -190.6% |
| 2021 | $37.3M | -45.5% | $37.3M | 100.0% | $-116,042,000 | -311.0% |
| 2020 | $68.4M | +19.0% | $68.4M | 100.0% | $-80,540,000 | -117.7% |
| 2019 | $57.5M | -3.4% | $57.5M | 100.0% | $-110,895,000 | -192.9% |
| 2018 | $59.5M | -16.9% | $59.5M | 100.0% | $-77,874,000 | -130.9% |
| 2017 | $71.6M | +376.1% | $71.6M | 100.0% | $-46,259,000 | -64.6% |
| 2016 | $15.0M | +95.1% | $15.0M | 100.0% | $-59,586,000 | -396.1% |
See CTMX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs CTMX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare CTMX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonCTMX — Frequently Asked Questions
Quick answers to the most common questions about buying CTMX stock.
Is CTMX's revenue growth accelerating or slowing?
CTMX revenue declined -79.9% year-over-year, contrasting with the 5-year CAGR of +2.2%. TTM revenue fell to $36M. This reverses the prior growth trend.
What is CTMX's long-term revenue growth rate?
CytomX Therapeutics, Inc.'s 5-year revenue CAGR of +2.2% reflects the variable expansion pattern. Current YoY growth of -79.9% is below this long-term average.
How is CTMX's revenue distributed by segment?
CTMX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.